
House Energy and Commerce Committee Chairman Greg Walden (R-Ore.) said Tuesday that dealing with high drug prices will be “high on our agenda.”
The comments come after Walden attended a meeting at the White House earlier in the day with President Trump and the CEOs of several major drug companies, at which Trump pressed the companies to bring their prices down.
However, Walden pointed to solutions that are less far-reaching than what Democrats and Trump have proposed, such as allowing Medicare to negotiate drug prices. Instead, Walden said there could be legislation to speed up the Food and Drug Administration’s approval process for a new competitor to a drug that currently lacks competition.
Walden said that implementing the 21st Century Cures Act, passed by Congress last year, to speed up the FDA’s approval process, is also an important part of the picture.
Trump has gone farther than most Republicans in the past on drug prices, calling for Medicare to negotiate. Trump did not directly call for that policy on Tuesday, though.
Getting any drug pricing legislation through Congress would be a tall task, given how fraught the issue is and the resistance of many Republicans to government action on the issue.





